Stimuli-responsive graphene oxide and methotrexate-loaded magnetic nanoparticles for breast cancer-targeted therapy.
Mitra DolatkhahNastaran HashemzadehMorteza MahmoudiKhosro AdibkiaAyuob AghanejadMohammad Barzegar-JalaliHossein OmidianYadollah OmidiPublished in: Nanomedicine (London, England) (2021)
Aim: Nanocomposites of graphene oxide (GO) loaded with PEGylated superparamagnetic iron oxide nanoparticles and grafted with methotrexate and stimuli-responsive linkers (GO-SPION-MTX) were developed for photothermal and chemotherapy of breast cancer. Methods: PEGylated SPIONs were synthesized and conjugated with chemotherapeutic targeting agent MTX, which were then loaded on GO to prepare GO-SPION-MTX nanocomposites. To evaluate the photothermal effect of the nanocomposites, they were examined in breast cancer cell lines with low doses of near-infrared (NIR) laser radiation with/without acetazolamide. Results: The GO-SPION-MTX nanocomposites were found to be internalized by the folate-receptor-positive cancer cells and induce high cytotoxicity on exposure to NIR laser rays. Conclusion: Our findings suggest that the GO-SPION-MTX nanocomposite can potentially be used as a multimodal nanomedicine/theranostic against breast cancer.
Keyphrases
- cancer therapy
- photodynamic therapy
- drug delivery
- reduced graphene oxide
- iron oxide nanoparticles
- drug release
- carbon nanotubes
- magnetic nanoparticles
- fluorescence imaging
- high dose
- squamous cell carcinoma
- wound healing
- gold nanoparticles
- low dose
- breast cancer risk
- young adults
- high resolution
- radiation induced
- radiation therapy